{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:51:42Z","timestamp":1769755902176,"version":"3.49.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Celgene International S\u00e0rl"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Azacitidine (Vidaza<jats:sup>\u00ae<\/jats:sup>) is the standard treatment for patients with higher\u2010risk myelodysplastic syndromes (MDS) not eligible for allogeneic stem cell transplantation. In the noninterventional study PIAZA, we evaluated the effectiveness and safety of azacitidine treatment in 149 patients with higher\u2010risk MDS, chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) in routine clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Patients were treated according to physician's discretion. Besides evaluation of safety and effectiveness, impact of covariates on progression\u2010free survival (PFS) was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median age of patients was 75\u00a0years. 61.1% of patients were diagnosed with MDS, 31.5% with AML and 7.4% with CMML. Patients were treated with azacitidine for a median of seven cycles. Median PFS was 10.9\u00a0months. Median OS was 14.1\u00a0months. Two\u2010year survival rate was 28.9%. 45.9% of patients showed CR or PR. Stable and progressive disease were observed in 37.2% and 8% of patients, respectively. Transfusion independence was reported in 64 of 89 patients. Eastern cooperative oncology group (ECOG) performance status (PS) and red blood cell (RBC) transfusion before azacitidine therapy were identified as predictive factors for PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, we estimated the duration of PFS in a real\u2010world setting and identified ECOG PS and RBC transfusion as predictive factors for PFS. The safety of azacitidine showed a similar profile as demonstrated in the pivotal clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13160","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T07:03:51Z","timestamp":1533798231000},"page":"766-773","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study)"],"prefix":"10.1111","volume":"101","author":[{"given":"J\u00fcrgen","family":"Wehmeyer","sequence":"first","affiliation":[{"name":"H\u00e4matologisch\u2010onkologische Gemeinschaftspraxis M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Zaiss","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr interdisziplin\u00e4re Onkologie &amp; H\u00e4matologie Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Losem","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr Onkologie und H\u00e4matologie Neuss Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis f\u00fcr H\u00e4matologie und Onkologie K\u00f6ln Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Niemeier","sequence":"additional","affiliation":[{"name":"iOMEDICO Clinical Research Organization Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Harde","sequence":"additional","affiliation":[{"name":"iOMEDICO Clinical Research Organization Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Verena","family":"Hannig","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis Dres. Pott\/ Tirier\/ Hannig Bottrop Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanns\u2010Detlev","family":"Harich","sequence":"additional","affiliation":[{"name":"Onkologische Schwerpunktpraxis Hof Hof Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"iOMEDICO Clinical Research Organization Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Klausmann","sequence":"additional","affiliation":[{"name":"Studienzentrum Aschaffenburg Aschaffenburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Werner","family":"Tessen","sequence":"additional","affiliation":[{"name":"Studienzentrum MVZ Onkologische Kooperation Harz Goslar Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-9624","authenticated-orcid":false,"given":"Karin","family":"Potthoff","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr interdisziplin\u00e4re Onkologie &amp; H\u00e4matologie Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_2_6_4_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes","author":"National Comprehensive Cancer Network (nccn)"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn349"},{"key":"e_1_2_6_6_1","first-page":"121","article-title":"Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO\u2010defined acute myeloid leukaemia compared with conventional care regimens: an update","volume":"2","author":"Fenaux P","year":"2008","journal-title":"Ecancermedicalscience"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404796"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_6_10_1","unstructured":"Common terminology criteria for adverse events (Schemper) \u2010 CTCAE_4.02_2009\u201009\u201015_QuickReference_8.5x11.pdf.https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/Archive\/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf(Accessed May 18 2016)."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.04.005"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25774"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01456.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.115"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1179\/2295333714Y.0000000102"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12595"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289280"},{"key":"e_1_2_6_19_1","first-page":"709a","article-title":"Response rates using International Working Group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine [abstract 2526]","volume":"106","author":"Silverman LR","year":"2005","journal-title":"Blood"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp258"},{"key":"e_1_2_6_21_1","unstructured":"HofmannW\u2010K PlatzbeckerU G\u00f6tzeK StauderR PasswegJ GermingU.Myelodysplastische Syndrome (MDS) Leitlinie.www.dgho-onkopedia.de. Accessed December 17 2015."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T20:07:57Z","timestamp":1694894877000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/ejh.13160"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13160","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"2017-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}